ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) – making a difference in neurology, Alexza Pharmaceuticals, Inc (NASDAQ:ALXA)

Posted by George Brook June 11, 2013 0 Comment 1548 views


ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) share prices had risen by 14.76% to close at $19.52/share at the close of trading on Monday. ACAD shares had been trading in the $17.05 to $20.09/share range which boosted the company to a new, 52-week high. The 52-week low price level is $1.32/share.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) focuses on developing and commercializing small-molecule drugs that are used in unmet neurological and other related central nervous system disorders’ unmet needs. Currently, the company has four product candidates in the pipeline and pimavanserin is its principal candidate. This drug is in the Phase III clinical study. It is being developed for the treatment of Parkinson’s disease psychosis. The company has been doing a lot of research in the neurology space as well as in the development of treatments for Glaucoma.

Alexza Pharmaceuticals
Another company that operates in the same segment is Alexza Pharmaceuticals, Inc (NASDAQ:ALXA). The company along with Teva Pharmaceutical Industries has just reached an exclusive license & supply agreement in the U.S, for Adasuve inhalation-powder. This is used for treating agitation that is associated with schizophrenia in adults. It is also called bipolar I disorder.

What is schizophrenia?
The exact cause of schizophrenia is still sort of a mystery. However, researchers believe that a mix of genetics and the environment are contributing factors to its development. Another contributing factor could be issues with some specific naturally-occurring brain chemicals such as the glutamate and dopamine neurotransmitters. Neuro-imaging studies have shown that there are distinct differences in the central nervous system and the brain structure of people who suffer from schizophrenia.

Though researchers are not positive about what the significance of these different changes is, they indicate that schizophrenia is essentially a brain disease. Nearly 4-5 million patients who suffer from schizophrenia or bipolar I disorder in the U.S. experience and also seek treatment for the agitation episodes.

ALXA will manufacture and supply Adasuve to Israel-based Teva. The latter will handle U.S commercial sales as well as clinical trials. It has gained the rights to conduct new clinical trials for certain new, potential-indications in other neurological disorders. Companies such as ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) and Alexza Pharmaceuticals, Inc (NASDAQ:ALXA) have been steady with their research and development activities with reference to neurological disorders.


About George Brook

George Brook covers money and politics for GDP Insider. George is a veteran journalist who has also covered Congress, national political conventions and presidential politics. George also covers the White House as well as economic and domestic policy for GDP insider. George's reporting has won numerous awards, including two Scripps Howard awards, two National Headliners, two Gerald Loeb Awards, as well as honors from Sigma Delta Chi and the National Press Club.

View all post by George Brook Visit author's website

Write Your Comment